Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DigitalOcean Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while DigitalOcean Holdings Inc trades at $128.05 (market cap $13.62B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× DigitalOcean Holdings Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DOCN | |
|---|---|---|
Market Cap | $39.89B | $13.62B |
Sector | Health | Technology |
52-Week High | $491.22 | $181.29 |
52-Week Low | $278.09 | $25.74 |
Enterprise Value | $38.15B | $14.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DigitalOcean (DOCN) trades at $130.49, down 7.38% over the past 24 hours, amid a bearish technical signal. The company reported strong Q1 2026 earnings of $0.44 per share, beating expectations, and anticipates record Q2 2026 results with remaining performance obligations exceeding $800 million. Revenue grew to $901.43 million in 2025, with a net income margin of 24.97%, though valuation ratios remain elevated with a P/E of 57.23. Analyst consensus is bullish with a $174.80 price target.
Outlook remains positive due to accelerating AI-driven cloud demand and strong execution, but risks include high valuation multiples, negative shareholder equity, and competitive pressure from hyperscalers. The stock offers growth potential if AI adoption continues, yet investors should monitor debt levels and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
